Integrating Non-Communicable Disease and HIV Treatment in Uganda
2020
Despite growing enthusiasm for integrating treatment of non-communicable diseases into human immunodeficiency virus (HIV) care and treatment services in sub-Saharan Africa, there is little evidence on the potential health and financial consequences of such integration. This article aims to study the cost-effectiveness of basic non-communicable disease-HIV integration in a Ugandan setting.
The article presents an epidemiologic-cost model to analyze, from the provider perspective, the cost-effectiveness of integrating hypertension, diabetes mellitus and high cholesterol screening and treatment for people living with HIV receiving antiretroviral therapy (ART) in Uganda. The study finds that providing services for hypertension, diabetes, and high cholesterol for Ugandan ART patients would reduce the overall cardiovascular disease risk among these patients, it would amount to about 2.4% of national HIV/AIDS expenditure, and would present a cost-effectiveness comparable to other stand-alone interventions to address non-communicable diseases in low- and middle-income country settings.
Integrating Non-Communicable Disease and HIV Treatment in Uganda
Source:
Sando D, Kintu A, Okello S, Kawungezi PC, Guwatudde D, Mutungi G, Muyindike W, Menzies NA, Danaei G, Verguet S. Cost-Effectiveness Analysis of Integrating Screening and Treatment of Selected Non-Communicable Diseases into HIV/AIDS Treatment in Uganda. Journal of the International AIDS Society 2020; 23. https://doi.org/10.1002/jia2.25507